Azienda Ospedaliera San Camillo Forlanini di Roma
Welcome,         Profile    Billing    Logout  
 12 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rigacci, Luigi
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated
2
37
Europe
Copanlisib, ALIQOPA
Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
12/24
12/24
FIL_DALYA, NCT04915248 / 2020-000409-94: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Recruiting
2
28
Europe
Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
Plasmablastic Lymphoma
01/25
01/25
FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting
2
47
Europe
Rituximab + Golcadomide (CC-99282)
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Non-Hodgkin Lymphoma
04/30
04/30
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting
2
118
Europe, Canada, US, RoW
Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA
Karyopharm Therapeutics Inc
Myelofibrosis, Moderate Thrombocytopenia
04/26
10/28
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
122
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
04/27
04/30
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Fransvea, Pietro
DACOSAD, NCT06428370: Damage Control Surgery Over the World in Acute Diverticulitis

Recruiting
N/A
300
Europe, RoW
Damage Control Surgery
Link Campus University
Diverticular Perforation, Open Abdomen
12/24
06/25
LOREPUP, NCT04447170: Laparoscopic Versus Open Repair of Peptic Ulcer Perforation

Recruiting
N/A
200
Europe
Simple repair or Graham technique
Gianluca Costa
Surgery, Emergencies, Peptic Ulcer Perforation
11/21
04/22
Luca, Leonardo De
MYTHS, NCT05150704: - MYocarditis THerapy With Steroids

Recruiting
3
288
Europe, US, RoW
Methylprednisolone, saline solution
Niguarda Hospital, Ministry of Health, Italy, Istituto Di Ricerche Farmacologiche Mario Negri, University of Milano Bicocca, Regione Lombardia
Myocarditis Acute
03/28
12/28
NCT06275113: BRING-UP Prevention

Recruiting
N/A
6000
Europe
Heart Care Foundation
Ischemic Heart Disease, Cerebrovascular Disorders, Peripheral Arterial Disease
06/26
06/26
AT-TARGET-IT, NCT05430828: Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

Recruiting
N/A
2000
Europe
Repatha (evolocumab); Praluent (alirocumab)
Federico II University
Hypercholesterolemia
03/24
03/24
Marini, Pierluigi
LOREPUP, NCT04447170: Laparoscopic Versus Open Repair of Peptic Ulcer Perforation

Recruiting
N/A
200
Europe
Simple repair or Graham technique
Gianluca Costa
Surgery, Emergencies, Peptic Ulcer Perforation
11/21
04/22
Ammirati, Enrico
CMP-MYTHiC, NCT06158698: Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine

Recruiting
3
80
Europe
Colchicine, Treatment, Placebo
Niguarda Hospital, European Union, Ministry of Health, Italy, Mario Negri Institute for Pharmacological Research, University of Milano Bicocca
Cardiomyopathies, Myocarditis, Inflammatory Cardiomyopathy, Heart Failure, Ventricular Arrythmia
05/26
05/28
MYTHS-MR, NCT05974462: Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

Recruiting
3
174
Europe
Methylprednisolone 125 MG, Solu-Medrol, IV saline solution 0.9%, sodium chloride
University Hospital, Antwerp, Niguarda Hospital
Acute Myocarditis
10/26
10/28
MYTHS, NCT05150704: - MYocarditis THerapy With Steroids

Recruiting
3
288
Europe, US, RoW
Methylprednisolone, saline solution
Niguarda Hospital, Ministry of Health, Italy, Istituto Di Ricerche Farmacologiche Mario Negri, University of Milano Bicocca, Regione Lombardia
Myocarditis Acute
03/28
12/28
US-IJVD-CHF, NCT03874312: Ultrasound-assessed Internal Jugular Vein Distensibility in Advanced Chronic Heart Failure (US-IJVD in CHF)

Active, not recruiting
N/A
200
Europe
Linear ultrasound (US) assessment of the internal jugular vein
Niguarda Hospital
Systolic Chronic Heart Failure, Congestion, Venous, Advanced Heart Failure
02/19
12/22
Johnston, Amanda
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

Recruiting
1
140
Europe, Canada, US, RoW
IKS03
Iksuda Therapeutics Ltd.
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
09/25
09/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rigacci, Luigi
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated
2
37
Europe
Copanlisib, ALIQOPA
Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
12/24
12/24
FIL_DALYA, NCT04915248 / 2020-000409-94: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Recruiting
2
28
Europe
Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
Plasmablastic Lymphoma
01/25
01/25
FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting
2
47
Europe
Rituximab + Golcadomide (CC-99282)
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Non-Hodgkin Lymphoma
04/30
04/30
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting
2
118
Europe, Canada, US, RoW
Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA
Karyopharm Therapeutics Inc
Myelofibrosis, Moderate Thrombocytopenia
04/26
10/28
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
122
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
04/27
04/30
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Fransvea, Pietro
DACOSAD, NCT06428370: Damage Control Surgery Over the World in Acute Diverticulitis

Recruiting
N/A
300
Europe, RoW
Damage Control Surgery
Link Campus University
Diverticular Perforation, Open Abdomen
12/24
06/25
LOREPUP, NCT04447170: Laparoscopic Versus Open Repair of Peptic Ulcer Perforation

Recruiting
N/A
200
Europe
Simple repair or Graham technique
Gianluca Costa
Surgery, Emergencies, Peptic Ulcer Perforation
11/21
04/22
Luca, Leonardo De
MYTHS, NCT05150704: - MYocarditis THerapy With Steroids

Recruiting
3
288
Europe, US, RoW
Methylprednisolone, saline solution
Niguarda Hospital, Ministry of Health, Italy, Istituto Di Ricerche Farmacologiche Mario Negri, University of Milano Bicocca, Regione Lombardia
Myocarditis Acute
03/28
12/28
NCT06275113: BRING-UP Prevention

Recruiting
N/A
6000
Europe
Heart Care Foundation
Ischemic Heart Disease, Cerebrovascular Disorders, Peripheral Arterial Disease
06/26
06/26
AT-TARGET-IT, NCT05430828: Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

Recruiting
N/A
2000
Europe
Repatha (evolocumab); Praluent (alirocumab)
Federico II University
Hypercholesterolemia
03/24
03/24
Marini, Pierluigi
LOREPUP, NCT04447170: Laparoscopic Versus Open Repair of Peptic Ulcer Perforation

Recruiting
N/A
200
Europe
Simple repair or Graham technique
Gianluca Costa
Surgery, Emergencies, Peptic Ulcer Perforation
11/21
04/22
Ammirati, Enrico
CMP-MYTHiC, NCT06158698: Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine

Recruiting
3
80
Europe
Colchicine, Treatment, Placebo
Niguarda Hospital, European Union, Ministry of Health, Italy, Mario Negri Institute for Pharmacological Research, University of Milano Bicocca
Cardiomyopathies, Myocarditis, Inflammatory Cardiomyopathy, Heart Failure, Ventricular Arrythmia
05/26
05/28
MYTHS-MR, NCT05974462: Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

Recruiting
3
174
Europe
Methylprednisolone 125 MG, Solu-Medrol, IV saline solution 0.9%, sodium chloride
University Hospital, Antwerp, Niguarda Hospital
Acute Myocarditis
10/26
10/28
MYTHS, NCT05150704: - MYocarditis THerapy With Steroids

Recruiting
3
288
Europe, US, RoW
Methylprednisolone, saline solution
Niguarda Hospital, Ministry of Health, Italy, Istituto Di Ricerche Farmacologiche Mario Negri, University of Milano Bicocca, Regione Lombardia
Myocarditis Acute
03/28
12/28
US-IJVD-CHF, NCT03874312: Ultrasound-assessed Internal Jugular Vein Distensibility in Advanced Chronic Heart Failure (US-IJVD in CHF)

Active, not recruiting
N/A
200
Europe
Linear ultrasound (US) assessment of the internal jugular vein
Niguarda Hospital
Systolic Chronic Heart Failure, Congestion, Venous, Advanced Heart Failure
02/19
12/22
Johnston, Amanda
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

Recruiting
1
140
Europe, Canada, US, RoW
IKS03
Iksuda Therapeutics Ltd.
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
09/25
09/27

Download Options